REG - Coiled Therapeutics - Total Voting Rights

Coiled TherapeuticsAnnouncement

01/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260401:nRSA9296Ya&default-theme=true

RNS Number : 9296Y  Coiled Therapeutics PLC  01 April 2026

 

1 April 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

 

Total Voting Rights

 

Coiled Therapeutics plc (AIM:COIL), announces, following the Company's recent
successful Admission to trading on AIM and for the purpose of the FCA's
Disclosure and Transparency Rules, that the total issued share capital of the
Company consists of 425,856,539 ordinary shares of 1p each ("Ordinary Shares")
with voting rights.

 

The Company does not hold any Ordinary Shares in treasury. Therefore, the
total number of voting rights in the Company is 425,856,539. This figure may
be used by shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or a change
to their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 

 

Enquiries:

 Coiled Therapeutics plc

 Sotirios Stergiopoulos (Chairman)                                          Via Burson Buchanan

 Sridhar Vempati (CEO)

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)  +44 (0)20 3470 0470

 David Hignell / Adam Cowl / Devik Mehta (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Shard Capital Partners LLP (Joint Broker)                            +44 (0)20 4530 6926

 Damon Heath

 CPS Capital Group Pty Ltd (Joint Broker)                             +61 (0)8 9223 2222

 Jason Peterson / David Valentino

 Burson Buchanan (Public Relations)                                   +44 (0)20 7466 5000

 Henry Harrison Topham / Jamie Hooper / Toto Berger

 

 

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology
company focused on developing innovative precision oncology therapies. Its
lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I
clinical trials in the USA (trials ID: NCT06136884).  Coiled Therapeutics is
actively enrolling patients to test for safety and efficacy in patients whose
cancer has progressed on other treatments.   The Company is also assessing
its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is
supported by a leadership team with a proven track record in drug development
and strategic backing from A2A Pharmaceuticals.

 

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small
molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3
(TACC3). TACC3 is a validated oncology target that is frequently overexpressed
in many aggressive, hard-to-treat solid tumours but is dispensable in normal
adult cells, providing a wide therapeutic window.

 

By selectively disrupting cancer-critical protein-protein interactions at the
TACC3 C-terminal domain, AO-252 induces mitotic and replication stress,
impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has
demonstrated the ability to cross the blood-brain barrier, addressing a
significant unmet medical need for the treatment of brain metastases.

 

The asset is currently in an ongoing Phase I open-label dose-escalation study
and early clinical signals have shown encouraging anti-tumour activity and a
benign safety profile, with the Company planning to initiate dose expansion
cohorts in lead indications, including prostate and ovarian cancer, during
2026.

 

For more information, please visit: www.coiledplc.com
(http://www.coiledplc.com/)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRWPUAWWUPQGQG



            Copyright 2019 Regulatory News Service, all rights reserved